Company Presentation
Immunophotonics
| Country: | Switzerland and USA |
| Category: | Clinical Stage Biotech Company |
| Room: | Rio |
| Date: | April 24, 2023 |
| Time: | 15:30 – 15:45 |
| Website: | www.immunophotonics.com |
| Speaker: | Dr. Theresa Visarius, Managing Director Immunophotonics Switzerland (IPS Biopharma AG) |
Company profile
Immunophotonics, Inc. is a privately owned clinical stage biotech that provides an innovative solution to combat solid metastatic cancers. The company is in phase 2 multi-indication clinical development of IP-001, an immune-stimulating drug designed to induce tumor-specific, potent antitumor immune activation. Early clinical data show shrinkage of both treated tumors and distant metastases. IP-001 is the first asset in clinical development from broad intellectual property.
